Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

15.06EUR
11:35am EDT
Change (% chg)

€-0.03 (-0.20%)
Prev Close
€15.09
Open
€15.15
Day's High
€15.27
Day's Low
€15.00
Volume
92,082
Avg. Vol
155,264
52-wk High
€19.56
52-wk Low
€9.09

Select another date:

Fri, Mar 31 2017

BRIEF-AB Science issues 1.2 mln new ordinary shares - Euronext

* AB Science SA issues 1,241,831 new ordinary shares, which will be listed on Euronext Paris market as of April 4, 2017 Further company coverage: (Gdynia Newsroom)

BRIEF-Ab Science announces that masitinib passed its non-futility test at 2 years

* Announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

BRIEF-AB Science announces positive results of final analysis from study AB10015

* Announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)

BRIEF-AB Science: phase 3 asthma fully enrolled

* A new phase 3 study has been initiated in asthma uncontrolled by high-dose inhaled corticosteroids and with elevated eosinophil level Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-AB Science issues 520,091 new shares

* Issues 520,091 new shares at a unit price of 14.62 euros ($15.54)/share Source text for Eikon: Further company coverage: ($1 = 0.9411 euros) (Gdynia Newsroom)

BRIEF-AB Science announces publication of pivotal phase 3 study masitinib results

* In pivotal phase 3 study masitinib administered at 6 mg/kg/day was significantly superior to placebo

Select another date:

More From Around the Web